Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practice

The potential for hepatitis B reactivation must be considered when switching people with HIV and prior hepatitis B exposure away from tenofovir-containing combined anti-retroviral therapy. Four cases of hepatitis B reactivation from the United Kingdom are presented. Hepatitis B mutations, risk factors and pre- and post-switch recommendations are explored.